Table 3. TEAEs that led to study withdrawal in ⩾1.0% of patients in either treatment group, stage 1 (SS; N=1055).

	PA21 (N=707) (%)	Sevelamer (N=348) (%)
Any TEAE	15.7	6.6
Diarrhea	2.8	0.6
Nausea	1.6	0.6
Abnormal product taste	1.6	0.3
Hyperphosphatemia	1.4	0.0
Constipation	1.0	1.4
Vomiting	1.0	0.6

Abbreviations: AE, adverse event; PA21, sucroferric oxyhydroxide; SS, safety set; TEAE, treatment-emergent AE.